Related Experiment Videos
Activation-induced cell death limits effector function of CD4 tumor-specific T cells
Rebecca R Saff1, Elena S Spanjaard, Andreas M Hohlbaum
1Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA.
Journal of Immunology (Baltimore, Md. : 1950)
|May 22, 2004
Summary
Tumor-specific CD4(+) T cells are crucial for immunotherapy. However, resistance to activation-induced cell death, mediated by Fas and Fas ligand, significantly enhances T cell persistence and anti-tumor immune responses.
Area of Science:
- Immunology
- Cancer Research
- T cell Biology
Background:
- Tumor-specific CD4(+) T cells augment immunotherapy but can undergo activation-induced cell death (AICD) due to Fas/Fas ligand upregulation under chronic stimulation.
- This AICD can lead to a loss of effector activity, limiting therapeutic efficacy in the context of high tumor burden.
Purpose of the Study:
- To investigate the impact of T cell persistence on immunotherapy outcomes.
- To evaluate the role of Fas-mediated AICD in regulating effector T cell function against tumors.
Main Methods:
- Utilized DO11 Th1 cells from wild-type, Fas-deficient, and Fas ligand-deficient mice.
- Employed an experimental model with a tumor antigen comprising an OVA-derived transmembrane fusion protein.
- Assessed T cell responses in vitro and in vivo, monitoring tumor growth and regression.
Main Results:
- Fas-deficient DO11 Th1 cells exhibited prolonged survival, leading to more sustained tumor-specific responses.
- Both Fas- and Fas ligand-deficient Th1 cells demonstrated enhanced ability to delay tumor growth and induce regression compared to wild-type cells.
- Resistance to AICD was correlated with improved T cell effector activity.
Conclusions:
- T cell persistence, achieved by evading AICD, is critical for effective anti-tumor immunotherapy.
- Targeting Fas-mediated apoptosis pathways could represent a strategy to enhance the efficacy of T cell-based cancer therapies.